Omega-3 DeficiencyNCT07753174
A Clinical Trial to Evaluate the Effects of an Omega-3-containing Supplement on DHA and EPA Levels in the Blood
A study testing Omega Active Supplement in people with Omega-3 Deficiency and DHA and EPA Blood Levels, run by Revive Active at 1 site in United States.
Trial summary
This is a 12-week, hybrid, single-arm clinical trial designed to evaluate the effects of an omega-3-containing supplement (Omega Active) on DHA and EPA levels in the blood. Forty participants will take two capsules of the test product daily and complete study-specific questionnaires at Baseline, Week 4, Week 8, and… Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Omega-3 Deficiency, DHA and EPA Blood Levels, Cardiovascular Health
- What is being tested?
- Omega Active Supplement
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 49 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2026to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Be male or female.
- Be aged 18-65.
- Anyone in good general health.
- Willing to avoid taking other supplements, prescription medications, or herbal remedies that target DHA or EPA levels in the body, for the duration of the study.
- Must not have taken fish oil or plant-based omega oil supplements in the past eight weeks.
- Willing to maintain their current diet, sleep schedule, and activity level for the duration of the study.
- Resides in the United States.
Who cannot join
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone on anticoagulants or antiplatelet therapy.
- Anyone with a bleeding disorder.
- Anyone with any allergies or sensitivities to any of the study product ingredients.
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
- Anyone unwilling to follow the study protocol.
- Anyone who does not consume any specific dietary ingredients for any reason.
- Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Patrick Renner contact
United States1 site, 1 recruiting
- Recruiting
Citruslabs
Las Vegas, Nevada, 89101
About this study
This is a 12-week, hybrid, single-arm clinical trial designed to evaluate the effects of an omega-3-containing supplement (Omega Active) on DHA and EPA levels in the blood. Forty participants will take two capsules of the test product daily and complete study-specific questionnaires at Baseline, Week 4, Week 8, and Week 12, while also attending their local Quest Diagnostics Center at Baseline and Week 12 for blood biomarker testing.
The study will also assess participants' perceptions of the effects of the test product on cognitive performance, gastrointestinal symptoms, and overall health through self-reported questionnaires. There is no randomization or blinding; all participants will receive the active supplement for the full 12-week intervention period.
- Being tested
- Omega Active Supplement
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Omega Active SupplementDietary supplement
All participants receive one dose (two capsules) of the Omega Active omega-3 supplement daily for 12 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Omega Active Supplement | Experimental | Not described Receives: Dietary Supplement: Omega Active Supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in DHA levels in the blood
Change from Baseline in DHA blood concentration as assessed by blood biomarker testing (test code 92701) at Quest Diagnostics Center
Measured: Baseline and Week 12
Change in EPA levels in the blood
Change from Baseline in EPA blood concentration as assessed by blood biomarker testing (test code 92701) at Quest Diagnostics Center
Measured: Baseline and Week 12
Secondary outcomes (4)
Change in self-reported cognitive performance
Participant-reported perceptions of the effects of the test product on cognitive function as assessed by self-reported questionnaire
Measured: Baseline, Week 4, Week 8, and Week 12
Change in self-reported gastrointestinal symptoms
Participant-reported occurrence of gastrointestinal symptoms, including acid reflux, as assessed by self-reported questionnaire
Measured: Baseline, Week 4, Week 8, and Week 12
Change in self-reported overall health and well-being
Participant-reported perceptions of overall health and well-being as assessed by self-reported questionnaire
Measured: Baseline, Week 4, Week 8, and Week 12
Participant experience with consumption of the test product
Participant-reported experience of consuming the test product, including palatability and taste, as assessed by self-reported questionnaire
Measured: Baseline, Week 4, Week 8, and Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2026
- Study startSep 2026 (estimated)
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Omega-3 DeficiencyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 49 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Revive Active
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07753174
- Sponsor's protocol ID
- 20833
- Other IDs
- legacy-20833
- Status last verified
- Aug 2026
- First submitted
- 3 Aug 2026
- Last updated
- 7 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Evaluate the Effects of an Omega-3-containing Supplement on DHA and EPA Levels in the Blood
- ClinicalTrials.gov ID
- NCT07753174
- Acronym / sponsor ID
- 20833
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 49 participants (estimated)
- Lead sponsor
- Revive ActiveIndustry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- Sep 2026 (estimated)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 7 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a 12-week, hybrid, single-arm clinical trial designed to evaluate the effects of an omega-3-containing supplement (Omega Active) on DHA and EPA levels in the blood. Forty participants will take two capsules of the test product daily and complete study-specific questionnaires at Baseline, Week 4, Week 8, and Week 12, while also attending their local Quest Diagnostics Center at Baseline and Week 12 for blood biomarker testing.
The study will also assess participants' perceptions of the effects of the test product on cognitive performance, gastrointestinal symptoms, and overall health through self-reported questionnaires. There is no randomization or blinding; all participants will receive the active supplement for the full 12-week intervention period.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Omega Active Supplement | Experimental | Dietary Supplement: Omega Active Supplement |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Be male or female.
- Be aged 18-65.
- Anyone in good general health.
- Willing to avoid taking other supplements, prescription medications, or herbal remedies that target DHA or EPA levels in the body, for the duration of the study.
- Must not have taken fish oil or plant-based omega oil supplements in the past eight weeks.
Key exclusion criteria (8 listed)
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone on anticoagulants or antiplatelet therapy.
- Anyone with a bleeding disorder.
- Anyone with any allergies or sensitivities to any of the study product ingredients.
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Omega Active SupplementAll participants receive one dose (two capsules) of the Omega Active omega-3 supplement daily for 12 weeks. | Dietary supplement | Omega Active Supplement |
Primary outcome
Change in DHA levels in the blood
Time frame: Baseline and Week 12
Change from Baseline in DHA blood concentration as assessed by blood biomarker testing (test code 92701) at Quest Diagnostics Center
Change in EPA levels in the blood
Time frame: Baseline and Week 12
Change from Baseline in EPA blood concentration as assessed by blood biomarker testing (test code 92701) at Quest Diagnostics Center
4 secondary outcomes
Change in self-reported cognitive performance
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in self-reported gastrointestinal symptoms
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in self-reported overall health and well-being
Time frame: Baseline, Week 4, Week 8, and Week 12
Participant experience with consumption of the test product
Time frame: Baseline, Week 4, Week 8, and Week 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2026.
Related trials for Omega-3 Deficiency
Enrolling by invitation
Effect of Omega-3 Supplementation on Pregnant Outcomes and Inflammation Markers of Women Infected With HIV Using Antiretroviral Therapy
Pregnant HIV Positive Women
Enrolling by invitation
PROmega Pilot Study of Clinic-based DHA Blood Screening in Early Pregnancy
Nutrient Deficiency
RecruitingPhase 2
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
Cognitive Dysfunction, Alzheimer Disease
Recruiting
Omega-3 Fatty Acids, Neuroendocrine and Attention Deficit Hyperactivity Disorder (OMNeADHD)
ADHD, Children
Not yet recruiting
The Effects of a Dialysis-Specific Formula Rich in Branched-Chain Amino Acids, Omega-3, and Dietary Fiber on Nutritional Status
ESRD (End-Stage Renal Disease), Dialysis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Patrick Renner contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Omega Active Supplement in people with Omega-3 Deficiency and DHA and EPA Blood Levels, run by Revive Active at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Patrick Renner (4242450284), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in DHA levels in the blood (time frame: Baseline and Week 12). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026.